Patient-Derived Xenograft Models for Pancreatic Adenocarcinoma Demonstrate Retention of Tumor Morphology through Incorporation of Murine Stromal Elements
Open Access
- 1 May 2015
- journal article
- research article
- Published by Elsevier in The American Journal of Pathology
- Vol. 185 (5) , 1297-1303
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (5T32CA106493-09)
This publication has 16 references indexed in Scilit:
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United StatesCancer Research, 2014
- Transcriptional dissection of pancreatic tumors engrafted in miceGenome Medicine, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Patient-derived tumour xenografts as models for oncology drug developmentNature Reviews Clinical Oncology, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient miceNature Protocols, 2009
- Establishment of Human Colon Cancer Cell Lines from Fresh Tumors versus Xenografts: Comparison of Success Rate and Cell Line FeaturesCancer Research, 2007
- An In vivo Platform for Translational Drug Development in Pancreatic CancerClinical Cancer Research, 2006
- Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical TrialsJAMA, 2004
- Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trialsBritish Journal of Cancer, 2001